Q3 Trade Pfizer

29 Eki

Q3 results for Pfizer were solid, with adjusted earnings and revenue surpassing expectations. The current drop in share price seems excessive and may be driven by liquidity concerns rather than underlying performance issues. The significant decline in expected sales for COVID products is concerning, but overall, the fundamentals appear stable. This drop could present a buying opportunity if it’s mainly a liquidity grab

29 Eki

Not

28.8 needs some type of confirmation, whether it's a retest or very strong orders. This level is crucial for assessing the market's next move

29 Eki

Not

Small entry now 28.250

29 Eki

Not

locked in 50% with a 1.3% gain x40 levrage. Holding rest BOS